3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
195
Prostatic Neoplasms, Castration-Resistant
20
Neoplasm Metastasis
20
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Metastatic Castration-resistant Prostate Cancer
6
Neoplasms
5
Castration-resistant Prostate Cancer
5
Breast Neoplasms
5
Pancreatic Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Prostate Adenocarcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Carcinoma, Renal Cell
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Diseases
2
Ovarian Neoplasms
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Interventions
radium Ra 223 dichloride
2
pembrolizumab
2
enzalutamide
2
abiraterone
2
Injections
2
Abiraterone Acetate
2
niraparib
1
efineptakin alfa
1
darolutamide
1
capivasertib
1
cabazitaxel
1
apalutamide
1
Solutions
1
Radium-223
1
Prednisone
1
Pluvicto
1
PSMA-11
1
Lutetium-177
1
Lutetium
1
Docetaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
enzalutamide
×
Genitourinary
×
Clear all
NCT03903835
2025-04-09
ProBio
Karolinska Institutet
Phase 3
Recruiting
750 enrolled
NCT03896984
2021-12-29
PHENIX
Bayer
Completed
346 enrolled